Literature DB >> 16289435

Topical and systemic drug delivery to the posterior segments.

Patrick M Hughes1, Orest Olejnik, Joan-En Chang-Lin, Clive G Wilson.   

Abstract

The posterior segments of the eye are exquisitely protected from the external environment. This poses unique and fairly challenging hurdles for drug delivery. It is somewhat dogmatic that topical ocular delivery is insufficient to achieve therapeutic drug levels in the posterior segments. However, some drugs are currently challenging this dogma. In this review we investigate the constraints and challenges of drug delivery to the posterior segment. Additionally, we outline several potential absorption pathways that may potentially be exploited to deliver drug to the back of the eye. Data on several compounds that achieve therapeutic posterior segment concentrations after topical dosing is presented. Finally, the issues surrounding systemic delivery to the posterior segment are reviewed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16289435     DOI: 10.1016/j.addr.2005.09.004

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  65 in total

1.  Ophthalmic drug delivery systems for the treatment of retinal diseases: basic research to clinical applications.

Authors:  Henry F Edelhauser; Cheryl L Rowe-Rendleman; Michael R Robinson; Daniel G Dawson; Gerald J Chader; Hans E Grossniklaus; Kay D Rittenhouse; Clive G Wilson; David A Weber; Baruch D Kuppermann; Karl G Csaky; Timothy W Olsen; Uday B Kompella; V Michael Holers; Gregory S Hageman; Brian C Gilger; Peter A Campochiaro; Scott M Whitcup; Wai T Wong
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-11       Impact factor: 4.799

2.  Diffusion Regulation in the Vitreous Humor.

Authors:  Benjamin Tillmann Käsdorf; Fabienna Arends; Oliver Lieleg
Journal:  Biophys J       Date:  2015-11-17       Impact factor: 4.033

Review 3.  Polymeric micelles for ocular drug delivery: From structural frameworks to recent preclinical studies.

Authors:  Abhirup Mandal; Rohit Bisht; Ilva D Rupenthal; Ashim K Mitra
Journal:  J Control Release       Date:  2017-01-11       Impact factor: 9.776

4.  Pharmacokinetics of intravenously administered tigecycline in eye compartments: an experimental study.

Authors:  Muammer Ozcimen; Yasar Sakarya; Serap Ozcimen; Sertan Goktas; Rabia Sakarya; Ismail Alpfidan; Erkan Erdogan
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-08-23       Impact factor: 3.117

5.  Sclera-choroid-RPE transport of eight β-blockers in human, bovine, porcine, rabbit, and rat models.

Authors:  Rajendra S Kadam; Narayan P S Cheruvu; Henry F Edelhauser; Uday B Kompella
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-07-23       Impact factor: 4.799

6.  Topical administration of a multi-targeted kinase inhibitor suppresses choroidal neovascularization and retinal edema.

Authors:  John Doukas; Sankaranarayana Mahesh; Naoyasu Umeda; Shu Kachi; Hideo Akiyama; Katsutoshi Yokoi; Jon Cao; Zoe Chen; Luis Dellamary; Betty Tam; Adrienne Racanelli-Layton; John Hood; Michael Martin; Glenn Noronha; Richard Soll; Peter A Campochiaro
Journal:  J Cell Physiol       Date:  2008-07       Impact factor: 6.384

7.  Computer modeling of drug delivery to the posterior eye: effect of active transport and loss to choroidal blood flow.

Authors:  Ram K Balachandran; Victor H Barocas
Journal:  Pharm Res       Date:  2008-08-05       Impact factor: 4.200

8.  Nanomicelles: an emerging platform for drug delivery to the eye.

Authors:  Aswani Dutt Vadlapudi; Ashim K Mitra
Journal:  Ther Deliv       Date:  2013-01

Review 9.  Recent perspectives on the delivery of biologics to back of the eye.

Authors:  Mary Joseph; Hoang M Trinh; Kishore Cholkar; Dhananjay Pal; Ashim K Mitra
Journal:  Expert Opin Drug Deliv       Date:  2016-09-06       Impact factor: 6.648

Review 10.  Intraocular sustained-release delivery systems for triamcinolone acetonide.

Authors:  Saffar Mansoor; Baruch D Kuppermann; M Cristina Kenney
Journal:  Pharm Res       Date:  2009-01-28       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.